( -- More than 70 abstracts highlight VEL...)Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop,Health

CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced that data for VELCADE, the market leading therapy with unsurpassed single-agent efficacy for patients with previously treated multiple myeloma (MM), will be featured at the upcoming International Myeloma Workshop (IMW) in Kos, Greece, June 25-30, 2007.

"Clinical data to be presented next week will underscore the crucial role of VELCADE based therapies in the front-line multiple myeloma treatment setting. These results will show that the high complete response rates seen with VELCADE based combinations translate to some of the most impressive survival rates to date," said Deborah Dunsire, M.D., President and Chief Executive Officer, Millennium. "These are exciting data for the field of multiple myeloma as we see that combining the power of VELCADE with other active agents substantially prolonged the lives of patients."

VELCADE in Front-Line MM Patients

Previously presented data have shown that VELCADE based combinations produce very high complete and near complete response rates. Data presented at this conference are expected to provide further evidence that this benefit leads to prolonged survival. Abstract highlights include:

    -- Phase I / II Study of Upfront VELCADE, Lenalidomide and Dexamethasone

       in Multiple Myeloma: Early Results

         * Lead investigator: Paul Richardson, M.D., Dana-Farber Cancer

           Institute

         * Abstract #715; Poster session: Thursday 28th June, 4:30 p.m.

    -- Front-line VELCADE, Melphalan and Prednisone (VMP) in Elderly Multiple

       Myeloma Patients: Extended Follow-Up

         * Lead investigator: Maria-Victoria Mateos, M.D., PhD., Grupo Espanol

           de Multiple Myeloma

         * Abstract #718
'"/>




Page: 1 2 3 4 5 6 7 8 
Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy
Delivered High Post-Transplant Complete Remission Rate, a Critical
Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced
Complete Remission Rates as High as 54 Percent in Patients With
Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved
Survival Rates as High as 100 Percent in Newly Diagnosed Multiple
Myeloma Patients
4. Study Shows Velcade Plus Doxil Improves Survival in Previously
Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection
Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response
to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox
(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10
Days for Reducing the Risk of Venous Thromboembolism (VTE) in
Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018
Injection
9. Genta Announces Results of Phase 1 Study Using Genasense
Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at
Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta
(Talotrexin) for Injection at The American Association for Cancer
Research Annual Meeting